💬 Discussion
Two Greek thinkers examine a shared healthcare fund, hospital model and identical person counters.

Medicare For All

Bernie Sanders in the Senate and Pramila Jayapal and Debbie Dingell in the House reintroduced the Medicare for All Act on 29 April 2025, as they had in earlier Congresses. Republicans reject it as a government takeover that would end private insurance. No committee has voted on the bill.

  • 18 percent of the American economy went to health care in 2024, more per head than in any other country [1]
  • 28 million people had no health coverage at all in 2025 [12]
  • 8.3 percent of health spending goes to administration, against 2.7 percent in Canada [4]

The proposal

One federal program covers every resident for hospital, medical, dental, vision, mental health and long-term care, replaces private insurance and charges nothing at the point of care.

The debate

Supporters argue that health care is a right and that millions of people skip care they cannot afford. One payer, they say, would end the fight between doctors and insurers over bills. Opponents say it would raise everyone's taxes, lengthen waits, worsen care and take away private plans that people like. The House Rules Committee held the first hearing on the idea on 30 April 2019; no version of the bill has reached a committee vote.

  • “Today, there are millions of people who would like to go to a doctor but cannot afford to do so. This is an outrage.”

    argues for: Bernie Sanders, Independent, Vermont Press release, 29 April 2025

  • “With the passage of the Medicare for All Act, physicians can focus on healing patients, not battling insurers over denials and delays.”

    argues for: Diljeet K. Singh, Physicians for a National Health Program Press release, 29 April 2025

  • “Medicare for All would require all Americans to pay more in taxes, wait longer for care, and receive potentially worse care.”

    argues against: Tom Cole, Republican, Oklahoma House Rules Committee hearing, 30 April 2019

The analysis

Medicare For All

65% of the weight is for, 35% against.

An argument's weight combines three questions: how big the effect is, how certain it is and how much the good at stake matters. The larger the slice, the more the argument weighs.

For

Against

On the current analysis, Medicare for All is probably a good proposal, on a ledger whose two largest entries almost cancel.

Likely better

Likely better: Under the assumptions used, the proposal brings more than it costs in 88 of 100 model runs.

 Overall effect: very large

How strongly the proposal works overall, in five steps from very small to very large, comparable across all debates. The ring is always full, even when the overall effect is small; this step says how large it is.

The analysis leans toward the supporters, though less for the uninsured than for what changes for everyone else. Its two largest items almost cancel: the billing that ends with a single payer, and the extra care people use once it costs nothing. That extra care is the strongest argument against, and the debate hardly raises it. What tips the balance is that bills stop landing on whoever is ill, and lower prices; the lives saved, which supporters put first, weigh less. The waits that opponents warn of weigh about as much as the price cut behind them, while higher taxes count as no cost, because they replace premiums and bills.

In detail

All arguments

Arguments for5 arguments

Billing that stops

34points

Administration takes 8.3 percent of American health spending against 2.7 percent in Canada. Most of the difference is people on both sides of a transaction arguing about who pays for what.

Value 6 · OutputImpact 8.6Plausibility 6.5
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is real resources released: the claims departments, the prior-authorisation staff, the coding contractors, the collections agencies and the hours doctors spend on paperwork rather than patients. This site places that with economic output and prosperity, because what is freed is labour and capital that go on to produce something else, rather than money moving between two parties. It is a genuine saving and not a transfer: nobody receives the money that is no longer spent arguing about a bill. Nothing is counted for the people whose jobs those are, whose displacement appears among the costs. Nothing is counted for the reduction in patient time spent on paperwork, which is real and small next to this. The value sits in the middle-upper part of the scale, because what is freed is labour that goes on to produce something else.

Impact

Administration accounted for 8.3 percent of American health care expenditure against 2.7 percent in Canada, whose system is the closest existing model to the one proposed [4]. On the 5.3 trillion dollars of national health spending in 2024, the latest year of the national accounts, closing that gap entirely would save about 297 billion dollars a year [1]. Full convergence is not realistic — the American system has more providers, more sites of care and more of everything to administer — so 200 billion dollars is used, in a range from 100 billion to the whole gap of about 297 billion, which is roughly two thirds of it. That is counted at the ordinary weight for resources. The published modelling of billing and insurance-related costs specifically puts the reduction at between a third and a half of those costs under a single-payer design, which is consistent with the figure used. What is not counted is the administrative apparatus the new programme itself would need, which appears among the costs. The Impact is the largest on this side and the second largest in the evaluation, and it is the number single-payer advocates and their critics disagree about least.

▸ Show calculation ▾ Hide calculation
National health expenditure [1] 5.3 trillion dollars in 2024 at 1.16 to the euro 4,569 billion euro-equivalent a year
× Gap between the American and Canadian administrative shares measured in national accounts rather than modelled [4] 8.3 percent against 2.7 percent 255.86 billion euro-equivalent a year
× Share of the gap that the payment system accounts for Setting, range 100 billion dollars to the whole gap of about 297 billion: the American system has more providers and more sites of care to administer whatever the payer looks like [5] 200 billion dollars, about two thirds 172.41 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 8.62
Score 8.62 Impact × 6 Value × 6.5 Plausibility ÷ 10 = 34 of 100

Plausibility

The counterfactual is the American system as it stands, and the comparison is with countries that already run what is proposed. The design is a precedent transfer rather than an experiment: Canada, Taiwan and the Nordic systems all administer health care for a fraction of the American share, and the difference is measured in national accounts rather than modelled. What that comparison cannot establish is how much of the gap is the payment system and how much is everything else about the American health sector — more sites of care, more litigation, more product variety — which is the confounder and is unresolved. It is the reason the figure used is two thirds of the observed gap rather than all of it. Reverse causation does not arise. The published billing-cost models give a similar answer by a different route, which is what lifts this above a single comparison. The Plausibility is above the middle: several countries demonstrate the destination and how much of the distance is the payment system is not settled.

Evidence: Multiple precedents · plausibility at most 7 Evidence of effect: Controlled · at most 7

No bill for being ill

20points

Americans paid 556.6 billion dollars out of their own pockets for care in 2024, and it lands on whoever happens to be sick. Under this bill the same money is raised in tax and lands on everybody.

Value 5 · Household budgetsImpact 7.2Plausibility 5.5
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is money that households pay for care, priced at the middle of the scale like all money. What changes is not how much is paid but who pays it and when: today it lands on the household that is ill, in a lump, at the moment its earnings are most likely to have fallen; under the bill it is raised in tax across everybody. Only the difference between what a dollar is worth at those two addresses is counted here, not the whole sum — the same households pay for it through tax either way, so booking both ends at full size would be counting a household's own money against itself. Nothing is counted for the premiums that also disappear, because who ends up paying for those depends on a financing act the bill leaves to be written. The value is the middle of the scale, and only the difference in what a dollar is worth when it lands on the ill rather than on everybody is counted.

Impact

Out-of-pocket health spending in the United States came to 556.6 billion dollars in 2024, about 11 percent of all health spending [1]. It is heavily concentrated: the costliest five percent of patients account for roughly half of all health spending in a year, and medical bills remain among the largest single causes of consumer bankruptcy. Borne as it is today, that money carries an effective weight of about 1.3, in a range from 1.1 to 1.8 — a mixture of ordinary spending at the ordinary weight and catastrophic bills landing on households whose income has usually fallen at the same moment. Raised in tax across the whole population it would carry the ordinary weight of 1.0. Only the difference of 0.3 is counted, giving a Normalised Impact of 7.2 on the scale of this evaluation. This is a netted figure by declaration: the sum itself is not counted on either side, because the households paying the tax are substantially the households that were paying the bills. The Impact is the third largest here and it is a difference in weight rather than a sum of money, which is why it is smaller than the amount it concerns.

▸ Show calculation ▾ Hide calculation
Out-of-pocket health spending [1] 556.6 billion dollars in 2024 at 1.16 to the euro 479.83 billion euro-equivalent a year
× Difference in what a dollar is worth on the ill rather than on everybody Setting, range 1.1 to 1.8: the costliest five percent of patients account for about half of all spending, and medical bills are among the largest causes of consumer bankruptcy 1.3 against 1.0 143.95 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 7.2
Score 7.2 Impact × 5 Value × 5.5 Plausibility ÷ 10 = 20 of 100

Plausibility

That out-of-pocket costs go to zero is written into the bill, so the direction is not in question. The counterfactual is the present distribution of cost sharing. The counterfactual for the tax side is not written into the bill at all, which is the honest limit of this argument: the financing act would determine whether the replacement lands progressively, proportionally or regressively, and only the fact that it lands on everybody rather than on the ill is used here. The replacement is taken to be raised in tax at the ordinary weight of a public dollar, and the roughly 1.6 trillion dollars of private insurance spending that households and employers pay today, which also stop, are taken to be replaced the same way, at the same weight at both ends, so they net to nothing [1]. If the money were borrowed instead, the interest would fall on later taxpayers as a cost, and that path is not counted. The confounder that matters is the concentration figure: how much of the effective weight of 1.3 comes from genuinely catastrophic bills against ordinary co-payments is not measured for the American distribution, and the range reflects that. Reverse causation does not arise. The netting is declared rather than assumed: the same money is not counted as both a gain to households and a cost to them. The Plausibility is a little above the middle: the removal of cost sharing is statutory and the weight put on its present concentration is estimated.

Evidence: Projection · plausibility at most 6 Evidence of effect: Definitional

One schedule for every price

11points

Commercial insurers pay hospitals roughly twice what Medicare does for the same procedure. Paying everybody the Medicare rate moves about 400 billion dollars a year from providers to whoever funds the system.

Value 5 · Household budgetsImpact 4.3Plausibility 5
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is money that does not have to be raised because care costs less to buy, priced at the middle of the scale like all money. It is a transfer rather than a saving: the money stays in the economy, it simply stops going to hospitals, specialists and the people who own them. Only the difference in weight between where it comes from and where it goes is counted, which is why this argument is a quarter of the sum involved. The response of providers to being paid less is the argument opposite, as this site requires wherever a weighted transfer is booked. Nothing is counted for the reduction in medical debt collection, which is inside the argument about out-of-pocket costs. The value is the middle of the scale, and only the weight difference between provider incomes and the general public is counted.

Impact

Commercial insurers pay hospitals in the order of twice the Medicare rate for the same procedure, and physician payment shows a smaller but similar gap. Applying the Medicare schedule to everybody would move about 400 billion dollars a year from providers to whoever funds the system. Provider income is not concentrated in the way that, say, corporate profit is: it is a mix of physician incomes in the top tenth of the distribution, hospital margins that belong to companies and non-profits, and the wages of nurses and technicians around the middle. A blended weight of 0.75 is used, in a range from 0.5 to 0.95, against 1.0 for the general public that funds the system, so the difference counted is 0.25 — a Normalised Impact of 4.31 on the scale of this evaluation. If the cut fell mainly on staff wages rather than on physician incomes and margins, this argument would be close to zero. The Impact is a quarter of the money involved, because most of a payment cut lands on people whose dollar is worth much what everybody else's is.

▸ Show calculation ▾ Hide calculation
Money moved by paying every provider the Medicare rate [3] 400 billion dollars at 1.16 to the euro 344.83 billion euro-equivalent a year
× Difference in weight between provider incomes and the general public Setting, range 0.5 to 0.95: a mix of physician incomes in the top tenth, hospital margins, and the wages of nurses and technicians around the middle 0.75 against 1.0 86.21 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 4.31
Score 4.31 Impact × 5 Value × 5 Plausibility ÷ 10 = 11 of 100

Plausibility

The price gap is measured: hospital price transparency data and the published comparisons of commercial against Medicare rates establish it in a way that was not possible ten years ago. The counterfactual is the present mix of payers. What is not established is who inside a provider organisation bears a cut, and that is what the whole argument turns on: a hospital that loses a third of its commercial revenue may cut executive pay, close a service line, or freeze nursing wages, and nothing in the literature predicts which. That is the confounder and it is unresolved. Reverse causation does not arise. The chain has a further behavioural link — that the cut is actually implemented rather than bargained away — which the experience of every attempt to set health prices administratively suggests should not be assumed. The Plausibility is at the middle: the price gap is measured and who absorbs its removal is not.

Evidence: Precedent · plausibility at most 6 Evidence of effect: Mechanistic · at most 6

People who live

8.1points

About 28 million Americans had no coverage in 2025. When Medicaid expanded, mortality among the newly covered fell by 0.132 percentage points a year — a 9.4 percent reduction against the group's own rate.

Value 9.5 · LifeImpact 1.4Plausibility 6
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is people alive at the end of the period who would otherwise have died, with a tenth added on the same anchor for the families, as this site does wherever it counts avoidable death. It sits just below the top of the scale rather than at it because part of what coverage buys is illness treated rather than death avoided, and only the deaths are counted here. It is separate from the money above in the ordinary way: a household that would have paid the bill and got the treatment gains from that argument, and one that went without gains from this one. Nothing is counted for the illness that is treated without ever threatening a life, which is a large stream and is not estimated. The value sits just below the maximum: the stream is life, reached through care that is taken up rather than avoided.

Impact

About 28.0 million Americans had no health coverage in 2025, 8.3 percent of the population [12]. Miller, Johnson and Wherry, linking survey and administrative death records, found that the Medicaid expansions reduced annual mortality among the newly covered by 0.132 percentage points, a 9.4 percent reduction against that group's own rate [6]. Applied directly, 28 million people would give about 37,000 deaths avoided a year. Half of that is used, 18,480, in a range from 5,400 to 48,500, because the uninsured population as a whole is younger and healthier than the low-income adults that study followed, and because the randomised Oregon experiment found no measurable mortality effect on a smaller sample over two years. Valued at the figure this site uses for a life with a tenth added for the families, that is a Normalised Impact of 1.42 on the scale of this evaluation. The Impact is a sixth of the administrative saving, which is the arithmetic of comparing 18,500 lives with the cost of running the billing system of a sixth of an economy.

▸ Show calculation ▾ Hide calculation
Americans without health coverage [12] 2025 survey count, 8.3 percent of the population 28 million people
× Annual mortality reduction among the newly covered measured on linked survey and administrative death records around the Medicaid expansions [6] 0.132 percentage points 36,960 deaths a year
× Correction for a younger and healthier uninsured population Setting, range 5,400 to 48,500 deaths: the study followed low-income adults gaining Medicaid, and the randomised Oregon experiment found no significant mortality effect on a smaller sample [7] 50 % 18,480 deaths a year
× Value of a life, with a tenth added for the families the value of a statistical life used across this site and the surcharge this site applies to avoidable death 1.4 million euro-equivalent each, plus 10 percent 28.46 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 1.42
Score 1.42 Impact × 9.5 Value × 6 Plausibility ÷ 10 = 8.1 of 100

Plausibility

The counterfactual is comparable adults in states that did not expand Medicaid, which the study constructs by comparing expansion and non-expansion states around 2014 in linked survey and administrative data — a difference in differences with individual death records rather than aggregate rates, which is what makes it stronger than the earlier work on the same question. The confounder that matters is that expansion states differ from non-expansion states in more than Medicaid, and the paper addresses it by restricting to people who were eligible by income and by showing parallel pre-trends. Reverse causation does not arise from a state's expansion decision at the individual level. What holds the plausibility below what the design would allow is the transfer, which is large: the population studied was low-income adults gaining Medicaid, and the uninsured as a group are younger and healthier, which is why the figure used is half of what the estimate would give. The Oregon randomised experiment, which found no significant mortality effect, is the counter-evidence and it is smaller and shorter. The Plausibility is at the middle to upper part: the effect is measured on individual death records, and the group it was measured on is not the group this would cover.

Evidence: Study · plausibility at most 7 Evidence of effect: Quasi-experimental · at most 8

Illness that gets treated

2.2points

Most of what coverage does never reaches a death certificate: a depression treated, a prescription filled, a condition managed rather than left. The Oregon lottery measured that for people gaining Medicaid against a randomly chosen control group.

Value 9 · HealthImpact 0.5Plausibility 5.5
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is health gained short of death for the 28 million people who are covered for the first time: depression that is treated, pain that ends, a chronic condition that is managed. It belongs to the same class as the lives above and sits one step below the top of it, because what is gained here could also have been regained later, and a life cannot. What is counted is the person's own condition, not what anyone pays as a result; the cost of the care that produces it is counted in full on the other side, in the argument about care that is used because it is free. Nothing is counted for the already insured, whose additional care is taken to be worth what it costs. The value sits one step below the maximum: the stream is health itself, but health that can be regained.

Impact

About 28.0 million Americans had no coverage in 2025 [12]. What a covered year is worth in health, short of death, has been measured once against a random control group: Oregon drew names by lot for its Medicaid expansion in 2008, and two years on the people who were drawn showed a 30 percent lower rate of depression, more preventive care and far less financial strain, with no measurable difference in blood pressure, cholesterol or blood sugar [7]. The depression finding alone is worth roughly 0.014 healthy life years per covered year for that group. The uninsured as a whole are younger, healthier and somewhat less poor than Oregon's applicants, so 0.008 is used here, in a range from 0.004 to 0.015. Across 28 million covered years that is 224,000 healthy life years a year, a Normalised Impact of 0.45 on the scale of this evaluation. Only the outcome the trial actually found is booked; the physical markers it did not find are left out, and the deaths are in the argument above. The Impact is a third of the lives counted above, because a covered year buys a modest amount of measurable health across a very large number of people.

▸ Show calculation ▾ Hide calculation
Americans without health coverage [12] 2025 survey count 28 million people
× Healthy life years gained per covered year, short of death Setting, range 0.004 to 0.015: the Oregon lottery measured a 30 percent fall in depression and no change in blood pressure, cholesterol or blood sugar; that finding alone is worth about 0.014 healthy life years a year for Oregon's poorer applicants [7] 0.008 224,000 healthy life years
× Value of the healthy life years the value of a healthy life year used across this site 40,000 euro-equivalent each 8.96 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 0.45
Score 0.45 Impact × 9 Value × 5.5 Plausibility ÷ 10 = 2.2 of 100

Plausibility

The counterfactual is as clean as it gets in health research: the people who were not drawn in Oregon's lottery. Assignment was by lot among applicants, so the compared groups differ only in whether their name came up, and neither reverse causation nor selection into coverage can arise [7]. The confounder that would otherwise dominate — healthier or more organised people obtaining coverage — is removed by the draw itself. Two limits apply. The trial ran in one state on people poor enough to apply for Medicaid, and the 28 million uninsured are a broader and healthier group, which is why the figure is a little over half of what the trial would give. And the physical-health results were null, so the claim stays inside what the trial found: the mental-health stream and nothing else. The Plausibility is a little above the middle: the finding is randomised, and the group it was measured on is narrower than the group this would cover.

Evidence: Study · plausibility at most 6.5 Evidence of effect: Experimental · at most 8.5

Arguments against4 arguments

Care that is used because it is free

29points

When care costs nothing at the point of use, more of it is used. About a third of the extra care goes to the 28 million people who are covered for the first time and is counted in full, because what it buys them is counted on the other side. For everyone else, the randomised experiment that measured this found the extra care produced no detectable improvement in health for the average adult. Most of that care is worth something to the patient, but far less than it costs.

Value 5 · OutputImpact 9.5Plausibility 6
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is real resources consumed: appointments, scans, prescriptions and hospital days that are provided because nothing stands between the patient and the service. It is priced at the middle of the scale, and it is a genuine resource cost rather than a transfer, because the staff hours and the equipment are used up. Two parts are counted differently. The care that goes to the 28 million people covered for the first time is counted at its full cost, because what it does for them — lives, and illness treated short of death — is counted in two arguments on the other side, and a benefit that is booked must carry its cost. For the already insured, only the part of the additional care that is worth less than it costs is counted, and of that only the gap between what it costs and what it is worth; the part that does them good is taken to be worth what it costs and is booked on neither side. Nothing is counted for the crowding-out of urgent care by routine care, which is a separate consequence and appears in the argument after this one. The value is the middle of the scale, and the care of the newly covered is counted in full because its benefit is counted elsewhere.

Impact

Removing cost sharing raises use. The randomised health insurance experiment that measured this found that free care raised spending by roughly a third against a plan with substantial cost sharing, and — the finding that matters here — that the extra care produced no detectable improvement in health for the average adult, though it helped the poorest and sickest [8]. A six percent rise in national health spending is used, in a range from two to fifteen percent, which is well below the experimental figure because most Americans already have insurance with moderate cost sharing rather than none. On the 2024 spending of 5.3 trillion dollars, that is about 320 billion dollars of additional care [1]. About a third of it, in a range from a fifth to a half, goes to the 28 million people covered for the first time: the uninsured use roughly half the care of the insured, and covering them roughly doubles it. That third, about 106 billion dollars, is counted at its full cost, because the lives and the health it buys are counted on the other side. Of the remaining 212 billion dollars, sixty percent is treated as worth less than it costs, in a range from 30 to 85 percent: about 127 billion dollars. Worth less is not worth nothing: care that a patient takes up only once its price falls to zero was worth to that patient something between nothing and the price paid before, on average about half of it, and the insured paid about a fifth of the cost at the margin; the care is therefore taken to be worth a tenth of what it costs, in a range from nothing to half. The loss is the other nine tenths, about 114 billion dollars; the other forty percent is care that does the already insured good and is booked on neither side. Together that is about 220 billion dollars a year. The Impact is the largest cost here and it is somewhat larger than the administrative saving on the other side, which is the central trade in this debate.

▸ Show calculation ▾ Hide calculation
National health expenditure [1] 5.3 trillion dollars in 2024 at 1.16 to the euro 4,569 billion euro-equivalent a year
× Rise in use once care is free at the point of service Setting, range 2 to 15 percent: well below the third measured under randomisation, because most Americans already have insurance with moderate cost sharing rather than none [8] 6 % 274.14 billion euro-equivalent a year
× Share that goes to people insured already Setting, range a half to four fifths: the other third goes to the 28 million covered for the first time, added below two thirds 182.76 billion euro-equivalent a year
× Care of the already insured that is worth less than it costs Setting, range 30 to 85 percent: the randomised experiment found no detectable health improvement for the average adult from the extra care, though it helped the poorest and sickest; the remaining 40 percent is taken to be worth what it costs and is booked on neither side [8] 60 % 109.66 billion euro-equivalent a year
× Part of its cost that is lost Setting, range 50 to 100 percent: care taken up only once its price falls to zero was worth to the patient between nothing and the price paid before, on average half of it; the insured paid about a fifth of the cost at the margin, so the care is worth about a tenth of its cost. A loss of the whole cost would treat it as worth nothing 90 % 98.69 billion euro-equivalent a year
+ Care of the 28 million covered for the first time, counted in full Setting, range a fifth to a half: the uninsured use about half the care of the insured, and covering them roughly doubles it; this care is booked at full cost because the lives and the health it buys are counted on the pro side 274.14 billion euro-equivalent × one third 91.38 billion euro-equivalent a year
= Resources counted 98.69 + 91.38 190.07 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 9.5
Score 9.5 Impact × 5 Value × 6 Plausibility ÷ 10 = 29 of 100

Plausibility

The counterfactual is the same population under present cost sharing. The design behind the response is experimental: households were randomly assigned to plans with different cost sharing and their use was measured over three to five years, which is the strongest evidence anywhere in this evaluation. Its weakness is age and transfer — it was run between 1974 and 1982, on a working-age population, in a health system that no longer exists — and that is a real limit rather than a formality. The confounder that matters is what has changed since: care is now more supply-driven, more of it is prescribed rather than sought, and the price a patient faces may matter less than it did. That is named and unresolved. The second and larger uncertainty is not the response but the valuation: the experiment's finding that the extra care did not improve average health is what justifies treating most of it as worth less than it costs, and it is the single most contested result in American health economics. How much less is a setting: a tenth of the cost follows from what patients paid before, and the range up to half covers health value that patients do not see themselves. Reverse causation does not arise from random assignment. The Plausibility is above the middle: the response is measured under randomisation, in a health system half a century old.

Evidence: Study · plausibility at most 6.5 Evidence of effect: Experimental · at most 8.5

Waiting for the care

9.5points

Paying every provider the Medicare rate cuts hospital revenue by roughly a third in commercial-heavy markets while demand rises. Something has to give, and in every system that has tried this it is time.

Value 9.5 · HealthImpact 2Plausibility 5
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is health lost to delay: a hip replaced a year later, a diagnosis made at a later stage, a specialist appointment that takes four months. This site places that in the class it uses for life and health, one step below the top because most of what is lost is function and comfort rather than years. It is the required counterpart to the argument about paying every provider the Medicare rate, which is a weighted transfer and therefore carries its behavioural response on this side. Nothing is counted for the people who receive care sooner because somebody else is no longer jumping the queue with better insurance, which is a real effect in the other direction and is not estimated. The value sits just below the maximum, and this argument exists because a payment cut booked as a gain has to carry the response it provokes.

Impact

Two things push in the same direction at once: demand rises because care is free, and supply tightens because hospitals in commercial-heavy markets lose something like a third of their revenue while rural hospitals that already lose money on public patients lose their cross-subsidy entirely. The result in every system that pays administratively set prices for universal coverage is a queue. One million quality-adjusted life years a year are used, in a range from 200,000 to three million — a million years across 340 million people, or about one day of healthy life per American a year on average, which sounds small and is not, because it lands almost entirely on the minority who need something done. At the value this site uses for a healthy year that is a Normalised Impact of 2.0 on the scale of this evaluation. The figure is the most uncertain in this evaluation and it is the one that a phased implementation, a transition fund for rural hospitals, or a less aggressive fee schedule would most change. The Impact is a quarter of the largest cost here and it is the argument least anchored in any American measurement.

▸ Show calculation ▾ Hide calculation
Quality-adjusted life years lost to delay each year Setting, range 200,000 to 3 million: about one day of healthy life per American per year on average, landing almost entirely on the minority who need something done [4] one million 1,000,000 quality-adjusted years
× Value of the years the value of a healthy life year used across this site 40,000 euro-equivalent each 40 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 2
Score 2 Impact × 9.5 Value × 5 Plausibility ÷ 10 = 9.5 of 100

Plausibility

The counterfactual is the American system as it stands, with its shorter waits and its 28 million uninsured. The evidence is precedent rather than experiment: Canada, the United Kingdom and Australia all combine universal coverage with administratively set prices and all report waiting lists that the United States does not have. What that comparison cannot do is separate the payment system from the level of funding — those countries spend half what the United States does per head, and a single payer spending American amounts might not queue at all, which is the strongest counter-argument and is unresolved. The confounder is therefore funding level rather than payment design. Reverse causation does not arise. Nothing has measured what a payment cut of this size does to American capacity, because nothing of this size has been attempted, and the quantity here is a construction rather than a finding. The Plausibility is at the middle: every comparable system queues, and every comparable system also spends far less, so what is being observed may be the budget rather than the payer.

Evidence: Multiple precedents · plausibility at most 6 Evidence of effect: Mechanistic · at most 6

Moving 160 million people at once

1.9points

Roughly 160 million Americans would leave employer coverage, about 1.8 million people work in health insurance, and a federal agency would have to be built to pay every medical bill in the country. Spread across ten years, the move costs about 16 billion dollars a year.

Value 5 · Enforcement costImpact 0.7Plausibility 5.5
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is what a change of this size consumes on the way: the systems built, the staff hired and retrained, the claims processed twice while two systems run in parallel, and the working lives interrupted for people whose jobs disappear. It is priced at the middle of the scale, the level this site uses for the cost of running a rule, and it is a real cost rather than a transfer, because the hours are consumed. It is counted as an annual figure across the ten-year horizon of this evaluation rather than as a one-off, because that is how a transition of this size is actually paid for. Nothing is counted for the risk that the transition fails outright, which is not a cost but a different scenario. The value is the middle of the scale, and the transition is counted as an annual figure across the horizon rather than as a one-off.

Impact

About 160 million Americans hold employer-sponsored coverage and would move; roughly 1.8 million people work in health insurance and most of those jobs would not exist. A federal agency capable of paying every medical bill in the country would have to be built, and the existing programme it would be built on top of currently covers a fifth of the population. Three components are counted, each a one-off spread across the ten-year horizon. First, the displaced workers: three quarters of the 1.8 million lose their job, and each spends about nine months, in a range from three to eighteen, out of work before producing again, at about 58,000 dollars of output a year — 59 billion dollars. Second, the systems: a national claims and enrolment system for 340 million people at about 40 billion dollars, in a range from 15 to 100. Third, two years in which the new payer runs while the old system winds down, at 30 billion dollars a year, in a range from 15 to 60 — 60 billion dollars. That is about 159 billion dollars in all, in a range from about 70 to 410, or about 16 billion dollars a year across the ten years counted here. It excludes the administrative cost of the finished programme, which is inside the administrative saving on the other side rather than here, and it excludes the transition payments the bill itself provides for displaced workers, which are transfers rather than costs. The Impact is a fourteenth of the largest cost here, and unlike the others it stops once the change is complete.

▸ Show calculation ▾ Hide calculation
Output lost while displaced insurance workers are between jobs Setting, range 3 to 18 months out of work and 40,000 to 65,000 euro-equivalent (about 46,000 to 75,000 dollars) of output a year: most of the jobs in health insurance would not exist under the bill [2] 1.8 million jobs × 75 % displaced × 0.75 years × 50,000 euro-equivalent (about 58,000 dollars) 50.6 billion euro-equivalent, once
+ Building the national claims and enrolment system Setting, range 15 to 100 billion dollars: the largest administrative construction the government has attempted, built on top of a programme that already pays a fifth of the country's bills [3] 40 billion dollars at 1.16 to the euro 85.1 billion euro-equivalent, once
+ Two systems running in parallel Setting, range 15 to 60 billion dollars a year: the new payer runs while employer plans and insurers wind down 30 billion dollars a year × 2 years at 1.16 to the euro 136.8 billion euro-equivalent, once
÷ Spread across the ten-year horizon one-off costs are counted as an annual figure across the horizon of this evaluation, at the standard weight for resources ÷ 10 years, weight 1.0 13.7 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 0.69
Score 0.69 Impact × 5 Value × 5.5 Plausibility ÷ 10 = 1.9 of 100

Plausibility

The counterfactual is no change. The components are estimable and none of them is measured for a project of this size, because nothing of this size has been attempted. The chain is complete and its links are ordinary — systems have to be built, staff have to be retrained, two systems run in parallel for a period, displaced workers spend time out of work — and the size of each is judgement. The confounder that would raise the figure substantially is that large government technology projects overrun, and the one that would lower it is that the existing Medicare programme already pays a fifth of the country's medical bills and could be scaled rather than replaced; both are named and neither is resolved. Reverse causation does not arise. The insurance-sector job losses are the firmest part, since the employment figures are published and the bill's own transition provisions acknowledge them; the months out of work and the cost of the systems are settings, which is why each carries a range of a factor of three to six. The Plausibility is a little above the middle: every component is ordinary and the size of a transition on this scale has no precedent to be measured against.

Evidence: Projection · plausibility at most 6 Evidence of effect: Mechanistic · at most 6

Medicines that are not developed

0.3points

The American market pays roughly twice what other rich countries do for branded medicines and funds a corresponding share of the world's pharmaceutical research. A single buyer negotiating one price would change that.

Value 9.5 · HealthImpact 0.09Plausibility 3.5
▸ Show reasoning & sources ▾ Hide reasoning & sources

Value

The stream is health that never arrives: treatments that are not developed, or arrive later, because the revenue that would have funded them was negotiated away. It sits just below the top of the scale, in the class this site uses for life and health. The effect is global rather than American, and it is counted anyway, because a life year is priced the same here wherever it is lived. Nothing is counted for the money patients and governments save on medicines, which is inside the argument about paying every provider a single rate. Nothing is counted for research that is redirected rather than abandoned. The value sits just below the maximum, and the effect is counted although it falls mostly outside the United States, because this site prices a life year the same wherever it is lived.

Impact

Global pharmaceutical research runs at roughly 250 billion dollars a year and the American market supplies a disproportionate share of the revenue that funds it: about 45 percent of global medicine spending by value, in a range from 40 to 50 [10]. The budget office's analysis of single-payer designs put retail drug prices 6 percent below current law if the programme paid the average of today's prices, and 28 percent below if it paid what Medicare and Medicaid pay after rebates [11]. A cut of 30 percent in American drug revenue is used, in a range from 6 to 60 percent, the top end standing for a buyer that pushes branded prices most of the way towards those of other rich countries. Across the industry's global revenue that is a cut of about 13.5 percent, and at the published elasticity of new drug approvals to market size of about 0.23 it implies about 3.1 percent fewer new medicines [9]. New medicines are estimated to account for a substantial part of the annual gain in life expectancy across rich countries; five million quality-adjusted years a year globally is used as that contribution, in a range from one to fifteen million, so the full loss would be about 155,000 quality-adjusted years a year. That full loss is not reached within the ten years counted here: a medicine takes around a decade from research to approval, fewer approvals would begin to show after about five years, and the missing medicines would take several more to come into wide use. Three tenths of the full loss is therefore counted as the average across the ten years, in a range from a tenth to a half, on the same horizon as every other argument here: about 47,000 quality-adjusted years a year, a Normalised Impact of 0.09 on the scale of this evaluation. Every number in that chain is contested. Taken together, without assuming that all of them fall at their extremes at once, the result runs from about 0.0075 to 0.38 on the same scale, a factor of about fifty. The Impact is the smallest here, about a hundredth of the largest cost, and it is the argument whose chain has the most links and the least measurement.

▸ Show calculation ▾ Hide calculation
Global health gain attributable to new medicines each year Setting, range one to fifteen million: new medicines account for a substantial but disputed part of the annual gain in life expectancy across rich countries [9] five million quality-adjusted years 5,000,000 quality-adjusted years
× Cut in the industry's global revenue Setting, range 6 to 60 percent for the American cut and 40 to 50 percent for the American share: the budget office put retail drug prices 6 or 28 percent below current law under its two single-payer payment scenarios [10][11] 30 % of American drug revenue × 45 % American share of global spending = 13.5 % 13.5 percent
× Fewer new medicines, at full effect at a measured elasticity of new approvals to market size of about 0.23 [9] 13.5 % × 0.23 = 3.1 % 155,250 quality-adjusted years
× Share of the loss reached within the ten years counted Setting, range 0.1 to 0.5: a medicine takes about a decade to develop, fewer approvals begin to show after about five years, and the missing medicines take several more to come into wide use 0.3 46,575 quality-adjusted years
× Value of the years the value of a healthy life year used across this site, applied wherever the year is lived 40,000 euro-equivalent each 1.86 billion euro-equivalent a year
÷ Normalised Impact scale of this evaluation 20 billion euro-equivalent a point 0.09
Score 0.09 Impact × 9.5 Value × 3.5 Plausibility ÷ 10 = 0.3 of 100

Plausibility

The counterfactual is the present American pricing of branded medicines. The chain is named — lower prices, lower revenue, less research, fewer medicines, less health — and only the middle link has a measured parameter: the elasticity of new approvals to market size, estimated on the expansion of Medicare drug coverage and on demographic changes in market size. The confounder that matters is that pharmaceutical revenue and research spending are only loosely coupled, because much research is funded from capital markets on expectations rather than from current revenue, and because a large share of basic research is publicly funded already; that is named and unresolved. Reverse causation is a live concern for the elasticity itself, since firms lobby for the markets they expect to serve. The last link — from fewer medicines to less health — rests on an attribution that health economists dispute sharply. Because the chain is long and one of its links has a finding against it, this sits below the middle. The Plausibility is well below the middle: the mechanism is coherent, one link of five is measured, and the coupling between revenue and research is weaker than the argument needs.

Evidence: Mechanism · plausibility at most 6 Evidence of effect: Mechanistic · at most 6 Placement: Chain open · plausibility 3–3.5

Open: Other rich countries have negotiated branded prices down for decades, and approval counts by therapeutic area are published. Comparing research intensity against changes in the share of global revenue those countries supply would test the coupling directly and could carry this above 5.

How robust the result is

Under the assumptions used, the proposal brings more than it costs in 88 of 100 model runs.

gains more than it costscosts more than it gains

Each dot stands for 200 of the 20,000 model runs.

One thing is deliberately left out: who pays. The bill leaves the financing to a separate act, and a progressive tax and a payroll tax would produce different answers about winners and losers; what is counted is the reorganisation itself. Two numbers shape the result: how much of the administrative gap would disappear, set at about two thirds, and how much of the extra care used when it costs nothing is worth what it costs [1][4][5][8]. Provider incomes are weighted at three quarters of the general public's dollar, so only a quarter of the 400 billion dollars moved by the fee schedule counts [1][3]. Counted that way, the proposal comes out ahead in nearly nine of ten runs.

Show the distribution of the model runs

20,000 simulated futures

Likely better · 88 %

In 88 of 100 simulated futures the proposal brings more than it costs.

No effect is known exactly; every argument has a range. The calculation draws a possible size for each argument from its range 20,000 times and counts how often the benefits exceed the costs.

Net effect in points per future. Left of zero the drawbacks outweigh the benefits, right of zero the benefits win. Eight in ten futures fall between −4.3 and +75 points.
Scale and assessment

Scale of this evaluation: Normalised Impact, unitless and calibrated to this topic. For comparison, one point here corresponds to about 20 billion euro-equivalent a year.

Size class:very large

Effect very large (+690) · 65 % of the effect is positive

Areas show individual argument weights. The positive share of the effect nets out money transfers between the two sides; the probability of a positive net effect is determined separately.

How we score →

Review and sources

AI evaluation · not yet reviewed by a human

This evaluation was produced and sourced by an AI model; a human review is still pending. Figures and conclusions may still change. The review log is at the foot of the page.How review works →

Last reviewed by Claude Opus 5.5 · October 29, 2026 · 9× AI, not yet reviewed by a human
  1. October 29, 2026AI reviewClaude Opus 5.5record updated

    Transfer-Beine pro-2 und pro-4 als Netto-Buchung mit netto_grund dokumentiert, Zahlen und Bilanz unverändert.

  2. October 29, 2026AI reviewClaude Opus 5.5record updated

    Page texts for the new page layout (draft G) with quotes from primary sources; numbers unchanged.

  3. October 21, 2026AI reviewClaude Fable 5.1record updated

    Money amounts in argument texts stated in dollars per style-en.md; scores, chains and balance unchanged

  4. October 20, 2026AI reviewClaude Fable 5.1record updated

    Summary and scale note rewritten to the style of 20 Oct 2026; numbers unchanged

  5. October 16, 2026AI reviewClaude Opus 5.5record updated

    Research-loss range re-derived in quadrature (0.02–20.7 → 0.15–7.5, still wider than 25x and capped in the simulation); balance unchanged.

  6. October 14, 2026AI reviewClaude Opus 5.5re-scored

    Prüfbericht 11.10.: con-1 bucht beim geringwertigen Mehrverbrauch nur noch den Abstand zwischen Kosten und Wert (90 % statt voller Kosten, H08); Basiszahlen einheitlich auf CMS 2024 (5,3 Bio $, 556,6 Mrd $ Selbstzahlungen) und 28,0 Mio. Unversicherte 2025 (H09); r 0,635 → 0,650.

  7. September 14, 2026AI reviewClaude Opus 5re-scored

    Gesamtprüfung 08.09. nachgezogen: Mehrversorgung der Neuversicherten voll gebucht (con-1 I 161 → 197) plus pro-5 Gesundheit (8,3); Übergang zerlegt (con-3 51,7 → 13,7); Medikamente an CBO 28 % und 10-Jahres-Anlauf (con-4 9,2 → 1,86); Finanzierungspfad benannt; r 0,622 → 0,635.

  8. September 6, 2026AI reviewClaude Opus 5record updated

    i_spanne und normalisierung an allen 8 Argumenten, Eintrittsgruppe fee-schedule-bites, massstab_hinweis ohne r. Kategorie bleibt Besser (P(D>0) 0,88). Befund des Laufs: das Spannen-Werkzeug rechnet an Gewichts-Schritten zu eng, weil die Setzungsspanne dort die Differenz zu 1,0 skaliert und nicht das Gewicht — betrifft jeden genetteten Transfer im Bestand.

  9. September 6, 2026AI reviewClaude Opus 5First evaluation

    First evaluation: the reorganisation scored and the financing deliberately left out, because the bill leaves it to a separate act.

Evaluations are produced with AI support and reviewed on a schedule for new developments; human passes are marked separately.How we review →

Show all 12 sourcesHide sources
  1. Centers for Medicare and Medicaid Services: National health expenditure data and NHE fact sheet, 2024 accounts. cms.gov
  2. Congress.gov: H.R. 3069, Medicare for All Act. congress.gov
  3. Congressional Budget Office: Economic effects of five illustrative single-payer health care systems. cbo.gov
  4. Center for American Progress: Excess administrative costs burden the U.S. health care system. americanprogress.org
  5. Scheinker and colleagues, Health Services Research: Reducing administrative costs in US health care: assessing single payer and its alternatives. onlinelibrary.wiley.com
  6. Miller, Johnson and Wherry, Quarterly Journal of Economics: Medicaid and Mortality: New Evidence from Linked Survey and Administrative Data. academic.oup.com
  7. Baicker and colleagues, New England Journal of Medicine: The Oregon Experiment: effects of Medicaid on clinical outcomes. nejm.org
  8. RAND Corporation: The Health Insurance Experiment: a classic study speaks to the current health care reform debate. rand.org
  9. Dubois and colleagues, RAND Journal of Economics: Market size and pharmaceutical innovation. onlinelibrary.wiley.com
  10. IQVIA Institute: The Global Use of Medicines 2024: Outlook to 2028. iqvia.com
  11. Congressional Budget Office: How CBO Analyzes the Costs of Proposals for Single-Payer Health Care Systems That Are Based on Medicare's Fee-for-Service Program, Working Paper 2020-08. cbo.gov
  12. National Center for Health Statistics: Health insurance coverage: early release of estimates from the National Health Interview Survey, 2025. cdc.gov

More debates in this area

Likely worse · 14 %
Size: medium
Restore the Staffing Standard

Lift the moratorium and put the 2024 minimum nurse staffing rule for nursing homes back into force.
Very likely better · 99 %
Size: large
Restore the Enhanced Credits

Bring back the larger Marketplace premium credits that lapsed at the end of 2025, for three more years.
Unclear · 49 %
Size: large
Medicaid Work Requirements

From January 2027, adults in the Medicaid expansion group must show 80 hours a month of work, study or volunteering, half-time schooling, or earnings of at least 580 dollars a month to keep their coverage.
All debates in Health Coverage and Costs →